PTX-COVID19-B
PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco-based Eric Marcusson. in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021 in Toronto.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
PTX-COVID19-B
PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco-based Eric Marcusson. in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021 in Toronto.
has abstract
PTX-COVID19-B is a messenger R ...... not be manufactured in Canada.
@en
Wikipage page ID
67,145,871
page length (characters) of wiki page
Wikipage revision ID
1,022,445,408
Link from a Wikipage to another Wikipage
routes of administration
type
vaccine
@en
vaccine type
mrna
@en
wikiPageUsesTemplate
comment
PTX-COVID19-B is a messenger R ...... n January 26, 2021 in Toronto.
@en
label
PTX-COVID19-B
@en